ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACAD ACADIA Pharmaceuticals

Market Closed 12-12 16:00:00 EST

27.15

+0.47

+1.76%

盘后27.20

+0.05+0.18%

18:16 EST

High27.28	Low26.42	Vol1.40M
Open26.75	D1 Closing26.68	Amplitude3.22%
Mkt Cap4.59B	Tradable Cap3.15B	Total Shares169.18M
T/O37.65M	T/O Rate1.21%	Tradable Shares115.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACAD","market":"US","secType":"STK","nameCN":"ACADIA Pharmaceuticals","latestPrice":27.15,"timestamp":1765573200000,"preClose":26.68,"halted":0,"volume":1399090,"hourTrading":{"tag":"盘后","latestPrice":27.2,"preClose":27.15,"latestTime":"18:16 EST","volume":168661,"amount":4579236.31,"timestamp":1765581407547},"delay":0,"floatShares":115846212,"shares":169181817,"eps":1.541283,"marketStatus":"Market Closed","change":0.47,"latestTime":"12-12 16:00:00 EST","open":26.75,"high":27.279,"low":26.42,"amount":37654023.96525,"amplitude":0.032196,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.541283,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":26.68,"preHourTrading":{"tag":"盘前","latestPrice":26.73,"preClose":26.68,"latestTime":"09:25 EST","volume":4002,"amount":108273.293592,"timestamp":1765549501578},"postHourTrading":{"tag":"盘后","latestPrice":27.2,"preClose":27.15,"latestTime":"18:16 EST","volume":168661,"amount":4579236.31,"timestamp":1765581407547},"volumeRatio":0.8408219510374236,"impliedVol":0.4404,"impliedVolPercentile":0.592},"requestUrl":"/m/hq/s/ACAD","defaultTab":"news","newsList":[{"id":"2590501509","title":"FDA Approves Acadia Pharmaceuticals' DAYBUE STIX for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501509","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501509?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:00","pubTimestamp":1765544426,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration  has approved DAYBUE STIX  for oral solution, a new dye- and preservative-free powder formulation for the treatment of Rett syndrome in patients aged two years and older. The approval was based on bioequivalence studies showing comparable efficacy and safety to the original DAYBUE oral solution. DAYBUE STIX will be available on a limited basis in the first quarter of 2026 and more broadly in the second quarter of 2026. The original oral solution will remain available.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on December 12, 2025, and is sole","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL1BhPSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4139","ACAD","LU2065170008.USD","LU2065169927.USD","LU2065171402.SGD"],"gpt_icon":0},{"id":"2590450967","title":"ACADIA Pharmaceuticals Inc - Daybue Stix Will Be Available on a Limited Basis Starting in Q1 2026 and More Broadly Early in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590450967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590450967?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:00","pubTimestamp":1765544401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6R4XJQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065169927.USD","LU2065171402.SGD","BK4139","LU2065171311.SGD","ACAD","LU2065170008.USD"],"gpt_icon":0},{"id":"2590095445","title":"ACADIA Pharmaceuticals Announces FDA Approval of Daybue® Stix (Trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590095445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590095445?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:00","pubTimestamp":1765544401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6R4XJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD","ACAD","BK4139","LU2065171311.SGD"],"gpt_icon":0},{"id":"2590516720","title":"ACADIA Pharmaceuticals Is Maintained at Hold by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516720","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516720?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:25","pubTimestamp":1765459500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACAD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 08:25 ET (13:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","BK4139","BK4127","LU2065171402.SGD","SF","LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"2590567097","title":"U.S. RESEARCH ROUNDUP-BioNTtech, GE Vernova, Synopsys","url":"https://stock-news.laohu8.com/highlight/detail?id=2590567097","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590567097?lang=en_us&edition=fundamental","pubTime":"2025-12-11 15:10","pubTimestamp":1765437037,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-BioNTtech, GE Vernova, SynopsysDec 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BioNTech, GE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL8N3XH0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CL","ANAB","ANF","ALSN","U","BAC","AAOI","ALNY","AZO","BKR","LNG","AR","APP","ARGX","LU0061474960.USD","BMBL","BOOT","BK4566","CARG","CAT","CHWY","CMI","TXG","CQP","BK4196","CAG","CVX","CWST","GOOGL","BK4581","BK4139","WHD","CHYM","CRI","LU1043141123.HKD","DRI","AEO","ACAD","AUB","BNTX","ACVA","ADBE","CNM","CVNA","LU1720051108.HKD","LU1934455277.USD","LU2210149790.SGD","BBIO","LU0557290698.USD","BTSG"],"gpt_icon":1},{"id":"2589836171","title":"UBS Adjusts ACADIA Pharmaceuticals Price Target to $35 From $39, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2589836171","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589836171?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:48","pubTimestamp":1764866898,"startTime":"0","endTime":"0","summary":"Price: 26.34, Change: +0.46, Percent Change: +1.78","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"gpt_icon":0},{"id":"2588734810","title":"Should ACADIA’s Earnings Beat and Conference Highlights Require Action From ACADIA Pharmaceuticals (ACAD) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588734810","media":"Simply Wall St.","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588734810?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:42","pubTimestamp":1764805325,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals recently presented at Citi’s Annual Global Healthcare Conference 2025 in Miami, highlighting its progress in central nervous system and rare disease therapies.\nStronger-than-expected third-quarter earnings and analyst commentary on Nuplazid and Daybue’s commercial traction have sharpened investor focus on ACADIA’s growth profile.\nNow we’ll examine how ACADIA’s earnings beat and evolving analyst views may shape the company’s broader investment narrative.\nThe best AI...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/should-acadias-earnings-beat-and-conference-highlights-requi","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/should-acadias-earnings-beat-and-conference-highlights-requi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ACAD","ISBC"],"gpt_icon":0},{"id":"2588054781","title":"ACADIA Pharmaceuticals Is Maintained at Neutral by Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2588054781","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588054781?lang=en_us&edition=fundamental","pubTime":"2025-12-02 23:29","pubTimestamp":1764689340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACAD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2025 10:29 ET (15:29 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MFG","ACAD"],"gpt_icon":0},{"id":"2588708783","title":"U.S. RESEARCH ROUNDUP- Green Brick Partners, Pultegroup, Toll Brothers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588708783","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588708783?lang=en_us&edition=fundamental","pubTime":"2025-12-02 15:06","pubTimestamp":1764659172,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Green Brick Partners, Pultegroup, Toll BrothersDec 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nL8N3X8089:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRBK","LU2112291526.USD","BK4096","IQV","KBH","ULTA","MRP","LU0079474960.USD","DE","MDB","LU1057294990.SGD","LU2211817866.USD","LU1064131342.USD","LU1868837300.USD","LU2108987350.USD","LU0345770308.USD","LU0980610538.SGD","BV","EOLS","BK4123","DFH","LEN","DHI","FWONA","LU0211331839.USD","IE0004445239.USD","LU0882574139.USD","ROK","CELC","CRL","SDHC","LU0757428866.USD","EPR","LU0823417737.USD","LU2211815571.USD","FWONK","NVR","TKO","LU1988902786.USD","LU0432979614.USD","LU0456855351.SGD","CF","FTRE","ICFI","ACAD","LU1917777945.USD","PHM","BK4120","TOL"],"gpt_icon":1},{"id":"2585315777","title":"Acadia Pharmaceuticals to Join Citi Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585315777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585315777?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:06","pubTimestamp":1763672778,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals Inc. will participate in a fireside chat at Citi's 2025 Global Healthcare Conference on December 2, 2025, at 9:45 a.m. Eastern Time. A live webcast and an archived recording of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on November 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL4w6CBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","LU1162221912.USD","LU1244550221.USD","LU0648001328.SGD","BK4585","LU0128525689.USD","BK4207","IE00BSNM7G36.USD","LU0980610538.SGD","LU2462157665.USD","LU0130102774.USD","LU2360032135.SGD","LU2125154778.USD","LU1267930227.SGD","BK4139","LU1244550494.USD","BK4566","LU1366192091.USD","LU1791807156.HKD","LU2236285917.USD","LU2125154935.USD","LU0162691827.USD","LU0130517989.USD","LU0320765646.SGD","LU0106831901.USD","BK4588","LU0098860793.USD","LU2417539215.USD","LU2065171402.SGD","LU2065170008.USD","LU2065171311.SGD","BK4534","LU1244550577.SGD","LU0477156953.USD","LU1668664300.SGD","ACAD","LU1201861249.SGD","BK4504","LU0170899867.USD","LU0072461881.USD","LU2456880835.USD","LU0310800965.SGD","BK4559","LU2065169927.USD"],"gpt_icon":0},{"id":"2584804269","title":"ACADIA Pharmaceuticals Unveils Pipeline Expansion and Growth Strategy in Neurological and Rare Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2584804269","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584804269?lang=en_us&edition=fundamental","pubTime":"2025-11-18 17:18","pubTimestamp":1763457527,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals Inc. presented updates on its commercial performance and pipeline development at the Jefferies London Healthcare Conference. The company reported continued growth of its core franchise product, NUPLAZID, with third-quarter net sales reaching $177.5 million, a 12% increase year-over-year. Referrals and new prescriptions for NUPLAZID also saw year-over-year growth of 21% and 23%, respectively. Strategic investments in 2026 will include a 30% increase in customer-facing roles and a focus on newly diagnosed patients and physicians. The pipeline portfolio highlighted late- and early-stage candidates targeting neurological and rare diseases, including Alzheimer's disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor, tardive dyskinesia, Rett/Fragile X, Huntington's disease, and SYNGAP1. Several clinical trial milestones are anticipated through 2026 and 2027, including Phase 2 and Phase 3 study initiations and readouts. The company","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6HCJJj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065171402.SGD","BK4139","LU2065169927.USD","ACAD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2584678089","title":"ACADIA Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2584678089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584678089?lang=en_us&edition=fundamental","pubTime":"2025-11-18 01:34","pubTimestamp":1763400840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACAD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 12:34 ET (17:34 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD"],"gpt_icon":0},{"id":"2583535523","title":"Director Cashes Out: Major Stock Sale at ACADIA Pharmaceuticals!","url":"https://stock-news.laohu8.com/highlight/detail?id=2583535523","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583535523?lang=en_us&edition=fundamental","pubTime":"2025-11-13 10:16","pubTimestamp":1763000179,"startTime":"0","endTime":"0","summary":"New insider activity at ACADIA Pharmaceuticals ( ($ACAD) ) has taken place on November 12, 2025. Director James M. Daly recently sold 30,000 shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-cashes-out-major-stock-sale-at-acadia-pharmaceuticals-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-cashes-out-major-stock-sale-at-acadia-pharmaceuticals-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU2065171402.SGD","LU2065169927.USD","ACAD","LU2065171311.SGD","LU2065170008.USD"],"gpt_icon":0},{"id":"2583158110","title":"Director James M. Daly Reports Sale of ACADIA Pharmaceuticals Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583158110","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583158110?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:00","pubTimestamp":1762988439,"startTime":"0","endTime":"0","summary":"James M. Daly, Director of ACADIA Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2jJMNg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director James M. Daly Reports Sale of ACADIA Pharmaceuticals Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","LU2065170008.USD","LU2065169927.USD","BK4139","LU2065171402.SGD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2581023807","title":"ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581023807","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581023807?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:18","pubTimestamp":1762478287,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals Inc. (($ACAD)) has held its Q3 earnings call. Read on for the main highlights of the call. ACADIA Pharmaceuticals Inc. recen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acadia-pharmaceuticals-q3-2025-earnings-call-highlights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acadia-pharmaceuticals-q3-2025-earnings-call-highlights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACAD"],"gpt_icon":0},{"id":"2581914650","title":"ACADIA Pharmaceuticals: Hold Rating Amid Stable U.S. Performance and Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2581914650","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581914650?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:16","pubTimestamp":1762438560,"startTime":"0","endTime":"0","summary":"Analyst Sean Laaman from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals and increased the price target to $25.00 from $24.00. Se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/acadia-pharmaceuticals-hold-rating-amid-stable-u-s-performance-and-growth-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/acadia-pharmaceuticals-hold-rating-amid-stable-u-s-performance-and-growth-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACAD"],"gpt_icon":0},{"id":"1170005091","title":"Stock Track | ACADIA Pharmaceuticals Surges 5.24% Pre-Market on Strong Q3 Earnings, Despite Mixed Analyst Reactions","url":"https://stock-news.laohu8.com/highlight/detail?id=1170005091","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170005091?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:01","pubTimestamp":1762437670,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) stock soared 5.24% in pre-market trading on Thursday, following the company's impressive third-quarter earnings report. The biopharmaceutical firm significantly...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ACAD"],"gpt_icon":0},{"id":"2581093878","title":"ACADIA Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $25 From $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093878?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:00","pubTimestamp":1762434005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI2E6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171402.SGD","LU2065170008.USD","BK4139","LU2065171311.SGD","ACAD","LU2065169927.USD"],"gpt_icon":0},{"id":"2581711098","title":"RBC Cuts Price Target on ACADIA Pharmaceuticals to $32 From $34, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581711098","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581711098?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:57","pubTimestamp":1762433872,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $29.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"gpt_icon":0},{"id":"2581638300","title":"ACADIA Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2581638300","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581638300?lang=en_us&edition=fundamental","pubTime":"2025-11-06 18:17","pubTimestamp":1762424220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACAD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2025 05:17 ET (10:17 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acadia.com","stockEarnings":[{"period":"1week","weight":-0.0106},{"period":"1month","weight":0.1252},{"period":"3month","weight":0.1499},{"period":"6month","weight":0.2506},{"period":"1year","weight":0.573},{"period":"ytd","weight":0.4796}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.063686},{"month":2,"riseRate":0.666667,"avgChangeRate":0.025516},{"month":3,"riseRate":0.428571,"avgChangeRate":0.056582},{"month":4,"riseRate":0.428571,"avgChangeRate":0.000567},{"month":5,"riseRate":0.571429,"avgChangeRate":0.061282},{"month":6,"riseRate":0.5,"avgChangeRate":-0.015184},{"month":7,"riseRate":0.590909,"avgChangeRate":0.052638},{"month":8,"riseRate":0.545455,"avgChangeRate":0.014715},{"month":9,"riseRate":0.5,"avgChangeRate":0.023984},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.024848},{"month":11,"riseRate":0.454545,"avgChangeRate":0.031974},{"month":12,"riseRate":0.545455,"avgChangeRate":0.060003}],"exchange":"NASDAQ","name":"ACADIA Pharmaceuticals","nameEN":"ACADIA Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACADIA Pharmaceuticals,ACAD,ACADIA Pharmaceuticals股票,ACADIA Pharmaceuticals股票老虎,ACADIA Pharmaceuticals股票老虎国际,ACADIA Pharmaceuticals行情,ACADIA Pharmaceuticals股票行情,ACADIA Pharmaceuticals股价,ACADIA Pharmaceuticals股市,ACADIA Pharmaceuticals股票价格,ACADIA Pharmaceuticals股票交易,ACADIA Pharmaceuticals股票购买,ACADIA Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction